THE MYELODYSPLASTIC SYNDROMES FOUNDATION (MDSF) IS A GLOBAL NONPROFIT ORGANIZATION DEDICATED TO SUPPORTING PATIENTS AND CAREGIVERS AFFECTED BY MYELODYSPLASTIC SYNDROMES (MDS), A GROUP OF RARE AND LIFE-THREATENING BONE MARROW DISORDERS, AND THE HEALTHCARE PROFESSIONALS WHO CARE FOR THEM.SINCE OUR FOUNDING MORE THAN 30 YEARS AGO, WE HAVE REMAINED STEADFAST IN OUR MISSION TO ADVANCE RESEARCH, PROVIDE CRITICAL EDUCATION AND SUPPORT SERVICES, AND IMPROVE TREATMENT OPTIONS FOR THOSE IMPACTED BY MDS.
Executive compensation, broken down
Form 990 · Part VII & Schedule J · 4 reported individuals · Filing year 2024
Percentile bands compare each position's total pay with the same role at Diseases, Disorders & Medical Disciplines organizations in New York.
- Base
- $151k
- Bonus
- —
- Other
- —
- Benefits
- —
| Position | Base | Bonus | Other | Benefits | Total |
|---|---|---|---|---|---|
Executive Director (through 1/25) Median to 75th percentile | $151k | — | — | — | $156k |
Patient Care Director Highest Compensated Employee 10th to 25th percentile | — | — | — | — | $138k |
Development Director 25th percentile to medianvs Diseases, Disorders & Medical Disciplines peers nationwide | — | — | — | — | $128k |
Secretary Officer (Unspecified) | — | — | — | — | $96k |
Plus 6 unpaid individuals.
Browse compensation in Diseases, Disorders & Medical Disciplines →
Top pay as a share of expenses
In 2024, the highest total compensation at The Myelodysplastic Syndromes Foundation equaled 5% of the organization's total expenses. The median for diseases, disorders & medical disciplines organizations is 10%.
Based on 2,393 diseases, disorders & medical disciplines organizations, each measured at its most recent filing year with reported expenses and compensation.
Up 80%
from 2023
From $86k in 2023 to $156k in 2024.
Chief Executive Officer pay rose 80% from 2023 to 2024, while revenue fell 22%.
Pay for the position itself, not any one person. The officeholder may have changed between 2023 and 2024.
Among peers
Revenue and top compensation, plotted against similar organizations. This organization is highlighted in cyan.
Common questions about The Myelodysplastic Syndromes Foundation
What does the Chief Executive Officer of The Myelodysplastic Syndromes Foundation earn?
In 2024, the Chief Executive Officer of The Myelodysplastic Syndromes Foundation received $155,674 in total compensation. This pay is above the median (the midpoint) for Chief Executive Officer roles among Diseases, Disorders & Medical Disciplines organizations in New York, within the top half of comparable filings. Based on IRS Form 990 data.
How does Chief Executive Officer pay at The Myelodysplastic Syndromes Foundation compare with similar nonprofits?
Compared with the same role at Diseases, Disorders & Medical Disciplines organizations in New York, the 2024 pay of the Chief Executive Officer at The Myelodysplastic Syndromes Foundation falls between the median and the 75th percentile. In 2024, the highest total compensation at The Myelodysplastic Syndromes Foundation equaled 5% of the organization's total expenses. The median for diseases, disorders & medical disciplines organizations is 10%.
What are The Myelodysplastic Syndromes Foundation's revenue and expenses?
In 2024, The Myelodysplastic Syndromes Foundation reported $2M in total revenue and $3M in total expenses on its IRS Form 990.
Compare any role, sector, or revenue band
Build your own benchmark from millions of reported positions.
Learn More About Nonprofit Compensation
Guides to help you understand and use this data
Nonprofit Executive Director Salary
What nonprofit executive directors earn, what drives the number, and how to use public compensation data whether you are a candidate, a current ED, or a board member.
Read moreHow to Look Up Nonprofit Salaries
Two approaches to finding executive compensation at any tax-exempt organization, from raw IRS filings to searchable databases.
Read moreAre Nonprofit Salaries Public?
What IRS Form 990 discloses about executive compensation, who has to report it, and how to look it up.
Read more